Pfizer Inc. (NYSE: PFE) will present the latest results from its leading genitourinary (GU) portfolio at the American Society of Clinical Oncology Genitour...
Janssen-Cilag International NV, a Johnson & Johnson company, announced that the European Commission (EC) has granted marketing authorization (MA) to LA...
AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with unre...
Tevogen Bio Holdings Inc. (“Tevogen Bio” or “Company”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech d...
Bristol Myers Squibb (NYSE: BMY) announced results of an analysis from the three-arm Phase 3 CheckMate -8HW trial evaluating Opdivo® (ni...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai announced results from the Phase 3 LEAP-015 trial evaluating KEYTR...
Pfizer Inc. (NYSE: PFE) announced positive results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI® (encorafenib) in combination ...
CG Pharmaceuticals (CG Pharma), a clinical biopharmaceutical company located in the San Francisco Bay Area, was established as an independent entity i...
AbbVie (NYSE: ABBV) and Neomorph, Inc. announced a collaboration and option-to-license agreement to develop novel molecular glue degraders for multiple tar...
AstraZeneca, a global pharmaceutical company focused on developing life changing medicines, announced a C$820 million (US$570m) investment in Canada,...
GC Cell, a leading cell and gene therapy company, announced the successful completion of its first thought leadership symposium in Jakarta, Indonesia....
Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce that the prestigious medical journal Nature Medicine published the results of ...
Beckman Coulter Life Sciences, a global leader in laboratory automation and innovation, along with the Indiana University School of Medicine, have been a...
Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies fo...
© 2025 Biopharma Boardroom. All Rights Reserved.
